Puma Biotechnology's Nerinib approved for extended complementary treatment for early stage breast cancer patients

recently, the(http://of the http:// announced by theof the
http:// ofmedicines and, the argentineMedicines(http://, food andmedical device
s (http://Agency has approved Nerlynx for extended assistive treatment for patients with hormone-receptor-positive, HER2-positive (hyperexpression/amplify) early breast cancer patientsAbout Nerlynx
Nerlynx is a daily oral tyrosine kinase inhibitor (TKI) approved in the United States in July 2017 and the European Union in September 2018 for extended assisted treatment for HER2-positive early breast cancer patientsNerlynx is the firstdrug (http:// approved for HER2-positive breast cancer patients to reduce the risk of recurrence of invasive diseases after completion of the metabolite-positive treatment 　　In July, Puma submitted a supplementtoly new drug (http:// application (sNDA) to the U.S FDA (http:// to expand Nerlynx indications: for third-line treatment of HER2-positive metastatic breast cancer patients 　　Recently, the FDA also granted Nerlynx an orphan drug for the treatment of breast cancer brain metastasis patients 　　Neratinib is an oral, irreversible, pan-ErbB receptor tyrosine kinase inhibitor (TKI) that effectively inhibits Erbb1 and Erbb2, and its mechanism is different from Roche hercetine (clottacotable monoantigen) and breast cancer new drug Perjeta (patoberate monoantigen), the latter 2 are monoclonal antibody drugs, targeting HER2 receptors on the surface of HER2-positive cancer cells 　　Currently, Puma is developing three candidate drugs - PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 Nerlynx is an oral version of neratinib